Research Article
Low Magnesium Exacerbates Osteoporosis in Chronic Kidney Disease Patients with Diabetes
Table 4
Bone metabolic parameters levels for the CKD patients with osteoporosis by low and high serum Mg levels.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1) For patients with stages 3, 4, and 5 CKD, PTH is in the range of 35–70 pg/mL, 70–110 pg/mL, and 150–300 pg/mL, respectively. (2) For patients with stages 3 to 4 CKD, serum Ca should be maintained within normal range, 8.9–10.1 mg/dL, and serum P should be within 2.7–4.6 mg/dL. For patients with stage 5 CKD, serum Ca should be 8.4–9.5 mg/dL and serum P target should be 3.3–5.5 mg/dL. (3) Vitamin D deficiency is defined as a serum 25(OH)D level of less than 20 ng/mL and vitamin D insufficiency is defined as a serum 25(OH)D level of 20 to 30 ng/mL. Serum 1,25(OH)2D deficiency is defined as a serum 1,25(OH)2D level of less than 25.1 ng/mL. |